Development of a PorA/FetA meningococcal vaccine for broad protection against meningococcal disease: progression from pre-clinical studies to Phase I clinical trials in humans. (360G-Wellcome-091634_Z_10_Z)
In the UK, Neisseria meningitidis expressing the serogroup B capsule (MenB), causes 1500-2500 cases of invasive infection each year and is the leading infectious cause of death in childhood. Unfortunately, the serogroup B capsule is poorly immunogenic in humans due to its similarity with human antigens. Vaccine development has therefore focussed on subcapsular surface antigens, but has been hampered by their variability. We have found that expression of meningococcal surface proteins (including PorA and FetA), is highly structured, such that a limited repertoire of these proteins are associated with each of the hyper-invasive genotypes of meningococci. This provides the potential for prevention of MenB disease with a multivalent FetA/PorA vaccine which we have been developing since September 2007 supported by a Wellcome Trust Translation award. FetA is only expressed under iron-restricted conditions so a constitutively expressing strain has been constructed from which an outer membrane vesicle is being manufactured in Norway for a phase I study to evaluate the safety and immunogenicity of this vaccine as the proof of concept in humans. This submission for additional funding is requested to widen the scope of supporting epidemiological data, to cover an increase in costs of manufacturing, and strengthen the preclinical data that will underpin the potential utility of the vaccine.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 985100 |
Applicant Surname | Pollard |
Approval Committee | Innovations Strategy Panel |
Award Date | 2010-01-22T00:00:00+00:00 |
Financial Year | 2009/10 |
Grant Programme: Title | Strategic Translation Award |
Internal ID | 091634/Z/10/Z |
Lead Applicant | Prof Andrew Pollard |
Other Applicant(s) | Dr Ian Feavers, Prof Jeremy Derrick, Prof Martin Maiden |
Partnership Value | 985100 |
Planned Dates: End Date | 2014-11-30T00:00:00+00:00 |
Planned Dates: Start Date | 2010-09-01T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | South East |